APA (7th ed.) Citation

J, B., N, K., Y, M., P, B., T, B., M, Z., . . . JS, W. (2022). The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nature communications, 13(1), 6401. https://doi.org/10.1038/s41467-022-33746-3

Chicago Style (17th ed.) Citation

J, Bauer, et al. "The Oncogenic Fusion Protein DNAJB1-PRKACA Can Be Specifically Targeted by Peptide-based Immunotherapy in Fibrolamellar Hepatocellular Carcinoma." Nature Communications 13, no. 1 (2022): 6401. https://doi.org/10.1038/s41467-022-33746-3.

MLA (9th ed.) Citation

J, Bauer, et al. "The Oncogenic Fusion Protein DNAJB1-PRKACA Can Be Specifically Targeted by Peptide-based Immunotherapy in Fibrolamellar Hepatocellular Carcinoma." Nature Communications, vol. 13, no. 1, 2022, p. 6401, https://doi.org/10.1038/s41467-022-33746-3.